In This Section

Home / Advocate / Letters and Statements

Letters and Statements

ACCC writes and signs on to letters to Congress and the Administration to promote our policy interests. We also write advocacy statements, blog posts, and opinion pieces on a wide range of topics in cancer care. Questions related to health policy? Contact Matt Devino, MPH, Director, Cancer Care Delivery and Health Policy.

Follow ACCC (@ACCCBuzz) and Matt Devino (@matt_devino) on Twitter for late-breaking cancer policy news and announcements.

Latest Letters

  • ACCC Cautions Senate Leadership on Impacts of Prescription Drug Pricing Reform
    July 27, 2022

    In a letter to Senate Leaders Schumer and McConnell on the current version of a reconciliation package including prescription drug reform provisions, ACCC expressed concerns about the impact of Medicare drug price negotiation on Part B drug reimbursement. As proposed, these reimbursement cuts would significantly reduce beneficiary access to crucial medications and treatments and also threaten the financial viability of cancer programs and practices. ACCC encourages Congress to seek alternative solutions to reduce prescription drug costs that hold providers harmless.
    Read the Letter

  • ACCC and Leading Cancer Advocacy Groups Request Hearing on MCED Coverage
    July 12, 2022

    ACCC and six other leading cancer advocacy organizations sent letters to the House Committee on Energy and Commerce and the House Committee on Ways and Means requesting that they hold a legislative hearing on H.R. 1946, the Medicare Multi-Cancer Early Detection (MCED) Screening Coverage Act. This bill has been cosponsored by more than half of the U.S. House of Representatives, including 39 Energy and Commerce Committee members and 36 Ways and Means Committee members with strong bipartisan support.
    Read the Letters

  • ACCC Urges Congress to Address Access to Coverage and Cancer Care Affordability
    June 30, 2022

    In a letter to congressional leadership, ACCC joined nearly 40 organizations in asking Congress to enact important access to care policy priorities as part of the reconciliation package currently being considered. Specifically, we urge Congress to pass legislation that would permanently extend enhanced subsidies for health insurance plans on ACA marketplaces, permanently fix the Medicaid "coverage gap" for states that have not expanded their Medicaid programs, and enact a cap on out-of-pocket costs for the Medicare Part D program.
    Read the Letter

  • ACCC Submits Comments to FDA on Draft Guidance to Increase Diversity in Clinical Trials
    June 13, 2022

    The ACCC Community Oncology Research Institute (ACORI) Task Force submitted comments to the Food and Drug Administration (FDA) in response to the agency's draft guidance on Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials.
    Read the Letter

  • ACCC Asks Senate Leaders to Include Clinical Trial Diversity Provisions in PDUFA Reauthorization
    June 08, 2022

    In a letter to Senate Health, Education, Labor & Pensions (HELP) Committee leadership, ACCC and 71 other patient advocacy organizations urge the Committee to include House-passed clinical trials diversity provisions in the Senate version of the Prescription Drug User Fee Act (PDUFA) reauthorization package.
    Read the Letter

  • ACCC Urges Congress to Pass Legislation Improving Clinical Trial Diversity
    May 11, 2022

    Ahead of this year's Prescription Drug User Fee Act (PDUFA) reauthorization, ACCC and 88 other patient and provider advocacy organizations urged congressional leadership to pass legislation that would improve the diversity of enrollment in clinical trials. The letter expresses support for a number of policy proposals, including provisions from the DIVERSE Trials Act (H.R. 5030/S. 2706) and the DEPICT Act (H.R.6584).
    Read the Letter

  • ACCC Joins 400+ Organizations in Support of MCED Legislation
    May 05, 2022

    ACCC joined more than 400 organization from all 50 states to urge Congress to pass the Medicare Multi-Cancer Early Detection (MCED) Screening Coverage Act (H.R.1946/S.1873) this year. This legislation would create a pathway for MCED tests to be covered by the Medicare program following approval by the Food and Drug Administration (FDA).
    Read the Letter

  • ACCC Asks Congress to Increase Funding for Lung Cancer Research Program
    April 01, 2022

    ACCC joined nearly 70 provider and patient organizations in urging Congress to increase funding for the Lung Cancer Research Program within the Congressionally Directed Medical Research Program (CDMRP) in the Fiscal Year 2023 Defense appropriations bill. The letter asks Congress to increase funding for this program from $20 to $60 million to approximate the level of support necessary to fund high-quality research applications and to ensure that funding is commensurate with the impact of deaths attributable to lung cancer among Veterans Health Administration patients.
    Read the Letter

  • ACCC Submits Comments for Senate Finance Hearing on Prescription Drug Prices
    March 29, 2022

    In response to a Senate Finance Committee Hearing entitled "Prescription Drug Price Inflation: An Urgent Need to Lower Drug Prices in Medicare", ACCC submitted a statement for the record highlighting concerns with proposed drug pricing legislation.
    Read Letter

  • ACCC Encourages Congress to Fund Cancer Moonshot Initiatives
    February 25, 2022

    ACCC joined nearly 100 provider and patient organizations in supporting President Biden’s renewed Cancer Moonshot and its efforts to advance cancer prevention, early detection, treatment, and research. The letter asks Congress to provide necessary funding for the Moonshot’s initiatives.
    Read Letter

  • ACCC Urges Congress to Revise Drug Pricing Legislation
    February 01, 2022

    ACCC wrote a letter to Senate Finance Committee Chairman Ron Wyden and Ranking Member Mike Crapo regarding drug pricing legislation being worked on by members of Congress. The letter asks that Congress remove providers from the middle of proposed drug pricing negotiations between the federal government and drug manufactures, siting the potential for negative repercussions on cancer care providers and their patients. 
    Read Letter

  • ACCC Co-signs Letter to Establish Pathway for Telehealth Reform
    January 31, 2022

    ACCC was one of 336 organizations that signed onto a letter to Congress on January 31, 2022, in support of comprehensive telehealth reform. The recommendations aim to provide significant relief to patients and providers concerned about the commitment to telehealth after the end of the COVID-19 public health emergency.
    Read Letter

  • Medicare Multi-Cancer Early Detection Screening Coverage Act
    January 04, 2022

    ACCC—along with five cancer advocacy organizations—urged Congress to pass and President Biden to sign the bipartisan Medicare Multi-Cancer Early Detection Screening Coverage Act (S.1873/H.R.1946) to increase early-stage diagnosis and enable earlier treatment for a wider range of cancers.
    Read Letter

  • ACCC Supports Legislation to Increase Diversity in Clinical Trials
    November 15, 2021

    ACCC co-signed a letter in strong support of the passage of the Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act (H.R. 5030/S. 2706) to ensure more patients—regardless of their race, ethnicity, economic means, or geographic location—have a chance to enroll in clinical trials.
    Read Letter

  • ACCC Co-signs Letter to Address Impact of COVID-19 on Cancer Care
    April 07, 2021

    As part of World Health Day (April 7), ACCC has joined more than 290 organizations in signing a joint letter to raise awareness to the unique needs of patients with cancer during the COVID-19 pandemic and improve care access and health outcomes for this vulnerable population. Read ACCC President Krista Nelson, MSW, LCSW, OSW-C, FAOSW's statement on the importance of this action, the joint-signed letter, and more information on this initiative.
    Read News Release

Recent Advocacy News Releases